BiomX Inc.

BiomX Inc. (ticker: PHGE) is a clinical-stage biopharmaceutical company that completed its SPAC business combination with Chardan Healthcare Acquisitions Corp in October 2019, entering public markets within the biotechnology and precision medicine sector. Chardan Healthcare Acquisitions Corp, sponsored by Chardan Capital Markets, conducted its IPO in 2018 with a focus on healthcare targets, ultimately selecting BiomX, a phage therapy developer, as its merger partner. The company's 8-K filing dated March 18, 2024 reflects continued post-combination SEC reporting activity under accession number 0001213900-24-023201. BiomX develops bacteriophage-based therapeutics targeting diseases driven by specific bacterial populations. For complete SPAC deal histories, sponsor profiles, and filing analytics on BiomX and hundreds of other transactions, sign up for full data access at SpacDesk.